Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brotim is a fixed-dose combination ophthalmic solution containing the alpha-2 adrenergic receptor agonist brimonidine and the non-selective beta-adrenergic receptor antagonist timolol. Developed by Optho Pharma, it is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who require adjunctive or replacement therapy. Brimonidine works by reducing aqueous humor production and increasing uveoscleral outflow, while timolol decreases aqueous humor secretion. Together, these complementary mechanisms provide more effective IOP control than either agent alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Brotim.